TY - JOUR
T1 - Radiotherapy of prostate cancer: Impact of treatment characteristics on the incidence of second tumors
AU - Buwenge, Milly
AU - Scirocco, Erica
AU - Deodato, Francesco
AU - Macchia, Gabriella
AU - Ntreta, Maria
AU - Bisello, Silvia
AU - Siepe, Giambattista
AU - Cilla, Savino
AU - Alitto, Anna Rita
AU - Valentini, Vincenzo
AU - Strigari, Lidia
AU - Morganti, Alessio G.
AU - Cammelli, Silvia
PY - 2020
Y1 - 2020
N2 - Background: It has been hypothesized that radiotherapy (RT) techniques delivering radiations to larger volumes (IMRT, VMAT) are potentially associated with a higher risk of second primary tumors. The aim of this study was to analyse the impact of RT technique (3D-CRT vs IMRT/VMAT) on the incidence of second tumors in prostate cancer (PCa) patients. Methods: A retrospective study on 2526 previously irradiated PCa patients was performed. Patients were treated with 3D-CRT (21.3%), IMRT (68.1%), or VMAT (10.6%). Second tumors incidence was analysed in 3 categories: pelvic, pelvic and abdominal, and "any site". The correlation with RT technique was analysed using log-rank test and Cox's proportional hazard method. Results: With a median follow-up of 72 months (range: 9-185), 92 (3.6%) cases of second tumors were recorded with 48 months (range: 9-152) median interval from RT. Actuarial 10-year second tumor free survival (STFS) was 87.3%. Ten-year STFS in patients treated with 3D-CRT and IMRT/VMAT was 85.8 and 84.5%, respectively (p:.627). A significantly higher 10-year cumulative incidence of second tumors in the pelvis was registered in patients treated with IMRT/VMAT compared to 3D-CRT (10.7% vs 6.0%; p:.033). The lower incidence of second pelvic cancers in patients treated with 3D-CRT was confirmed at multivariable analysis (HR: 2.42, 95%CI: 1.07-5.47, p:.034). Conclusions: The incidence of second pelvic tumors after RT of PCa showed a significant correlation with treatment technique. Further analyses in larger series with prolonged follow-up are needed to confirm these results.
AB - Background: It has been hypothesized that radiotherapy (RT) techniques delivering radiations to larger volumes (IMRT, VMAT) are potentially associated with a higher risk of second primary tumors. The aim of this study was to analyse the impact of RT technique (3D-CRT vs IMRT/VMAT) on the incidence of second tumors in prostate cancer (PCa) patients. Methods: A retrospective study on 2526 previously irradiated PCa patients was performed. Patients were treated with 3D-CRT (21.3%), IMRT (68.1%), or VMAT (10.6%). Second tumors incidence was analysed in 3 categories: pelvic, pelvic and abdominal, and "any site". The correlation with RT technique was analysed using log-rank test and Cox's proportional hazard method. Results: With a median follow-up of 72 months (range: 9-185), 92 (3.6%) cases of second tumors were recorded with 48 months (range: 9-152) median interval from RT. Actuarial 10-year second tumor free survival (STFS) was 87.3%. Ten-year STFS in patients treated with 3D-CRT and IMRT/VMAT was 85.8 and 84.5%, respectively (p:.627). A significantly higher 10-year cumulative incidence of second tumors in the pelvis was registered in patients treated with IMRT/VMAT compared to 3D-CRT (10.7% vs 6.0%; p:.033). The lower incidence of second pelvic cancers in patients treated with 3D-CRT was confirmed at multivariable analysis (HR: 2.42, 95%CI: 1.07-5.47, p:.034). Conclusions: The incidence of second pelvic tumors after RT of PCa showed a significant correlation with treatment technique. Further analyses in larger series with prolonged follow-up are needed to confirm these results.
KW - 3D-conformal radiotherapy
KW - Intensity modulated radiotherapy
KW - Prostate neoplasms
KW - Second malignancy
KW - Volumetric modulated arc therapy
KW - 3D-conformal radiotherapy
KW - Intensity modulated radiotherapy
KW - Prostate neoplasms
KW - Second malignancy
KW - Volumetric modulated arc therapy
UR - http://hdl.handle.net/10807/147791
UR - http://www.biomedcentral.com/bmccancer/
U2 - 10.1186/s12885-020-6581-5
DO - 10.1186/s12885-020-6581-5
M3 - Article
SN - 1471-2407
VL - 20
SP - 90-N/A
JO - BMC Cancer
JF - BMC Cancer
ER -